Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_assertion type Assertion NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_head.
- NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_assertion wasGeneratedBy ECO_0000203 NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_provenance.
- NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_assertion wasDerivedFrom befree-2016 NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_provenance.
- NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_assertion SIO_000772 8637045 NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_provenance.
- NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_assertion evidence source_evidence_literature NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_provenance.
- NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_assertion description "[PSA level should be used with caution as an end point in clinical trials using suramin therapy for hormone-refractory prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1350115.RAfrmOVXFXXFMysjxBNcWUHCu3oNEj6PhZHzar8cApwcw130_provenance.